PetVivo Holdings, Inc. 8-K

What Happened
PetVivo Holdings, Inc. (including subsidiaries PetVivo Animal Health and PetVivo AI, Inc.) filed an 8‑K reporting that on March 13, 2026 it entered a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received $400,000 on March 13, 2026 and is scheduled to receive the remaining $600,000 on or before April 15, 2026. The investor also received an option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026. The securities were sold under Section 4(a)(2) and Regulation D; the purchaser represented they are an accredited investor and the shares will bear Rule 144 restrictive legends.

Key Details

• Subscription Agreement executed March 13, 2026; initial proceeds received $400,000.
• Remaining $600,000 of the $1,000,000 offering due on or before April 15, 2026.
• Investor granted an option to invest an additional $1,500,000 for 1,875,000 shares, anticipated by June 30, 2026.
• Securities issued are "restricted" under Rule 144; sale relied on private placement exemptions (Section 4(a)(2) and Reg D).

Why It Matters
This filing confirms near‑term cash inflows that can support operations or development activities without a public offering. For investors, note the immediate dilution from the 1,250,000 newly issued restricted shares and the potential further dilution if the $1.5M option is exercised. The use of Reg D/private placement means the shares are restricted and not freely tradable until transfer conditions under the Securities Act are met. The form of the Subscription Agreement is filed as an exhibit to the 8‑K for additional specifics.